Classification and mechanism of action
Ranitidine belongs to antisecretory drugs — medications that suppress hydrochloric acid secretion in the stomach. In the classification, it is a 2nd-generation $H_2$ histamine receptor blocker.
Mechanism of action: the drug acts as a competitive histamine antagonist. The target site of ranitidine is $H_2$ receptors located directly on the membrane of the gastric parietal cell. By blocking these receptors, the drug interrupts the stimulating signal from histamine, leading to decreased hydrochloric acid production.
Differential target diagnostics: to understand the pharmacological map of the GI tract, it is important to distinguish ranitidine's mechanism from other antisecretory classes:
- Proton pump inhibitors (PPIs) (e.g., omeprazole) — block $H^+/K^+$-ATPase activity. This is the most potent mechanism as it shuts down the final stage of secretion.
- M-cholinoblockers — act on other receptors: pirenzepine blocks $M_1$ receptors (at the ganglion and ECL cell level), while atropine blocks $M_3$ receptors (on the parietal cell).
- Gastrin antagonists (proglumide) — block gastrin receptors.
- Prostaglandin analogues (misoprostol) — stimulate PG receptors, suppressing cAMP synthesis.
Pharmacological features and advantages
As a 2nd-generation drug, ranitidine has several clinically significant differences from its predecessor, cimetidine (1st generation):
- High efficacy: acts as a more potent antisecretory agent.
- Duration of action: the effect persists for a long time (10 to 12 hours), allowing for a convenient dosing schedule of only twice daily.
- No effect on the metabolism of other drugs: this is a key advantage of its safety profile. Unlike cimetidine (which is a known inhibitor), ranitidine does not inhibit microsomal oxidation in the liver. It does not affect cytochrome P450 isoenzymes (including CYP2D6), so it can be safely combined with psychotropic drugs (haloperidol, tricyclic antidepressants), antiarrhythmics, and opioids (codeine) without fear of delayed elimination.
Side effects
The drug has a favorable safety profile and rarely causes side effects. In rare cases, the following may occur:
- Headache.
- Gastrointestinal tract: constipation.
Dosage forms and prescription writing
The drug (Ranitidin) is available for both enteral and parenteral use:
- Tablets: 0.15 g and 0.3 g. Standard oral dose is 0.15 g twice daily.
- Injectable solution: in 2.5% — 2 ml ampoules. Administered intravenously or intramuscularly at a dose of 0.05 g (corresponding to 2 ml of a 2.5% solution).
Tablet prescription example: ```latin Rp.: Tab. Ranitidini 0.15 D.t.d. N. 20 S. Take orally 1 tablet twice a day. ```
Ampoule prescription example: ```latin Rp.: Sol. Ranitidini 2.5% - 2 ml D.t.d. N. 10 in amp. S. Administer intramuscularly 2 ml (0.05 g) once a day. ```
Briefly: answers to topical questions
What side effects does ranitidine cause?
- Ranitidine has a good safety profile and rarely causes adverse reactions.
- Rare headaches may occur.
- Constipation is also among the potential side effects.
What are the indications for ranitidine?
- Prescribed to patients with peptic ulcer exacerbation for ulcer healing when proton pump inhibitors are ineffective or contraindicated.
- The addition of antisecretory drugs is indicated when enzymatic therapy lacks therapeutic effect or when a significant dose increase is required in cystic fibrosis.
What are the contraindications for ranitidine?
- Ranitidine is contraindicated in children under 12 years of age.
Ranitidine — Works for a long time (10–12 hours) and Does not touch the liver (does not inhibit microsomal oxidation, unlike cimetidine).
Class and exam questions
How does ranitidine differ from cimetidine?
Ranitidine (2nd generation) has a longer duration of action (10–12 hours), a more pronounced antisecretory effect, and does not inhibit microsomal oxidation, thus not disrupting the metabolism of other drugs.
What is the target site of ranitidine on the pharmacological map of the GI tract?
It is a competitive histamine antagonist and selectively blocks $H_2$ histamine receptors directly on the gastric parietal cell membrane.
Why is omeprazole considered a more potent antisecretory drug than ranitidine?
Omeprazole (a proton pump inhibitor) blocks $H^+/K^+$-ATPase — the final step in hydrochloric acid secretion, whereas ranitidine shuts down only one of the pathways stimulating the cell (the histamine pathway).
What else to study on this topic
- Proton pump inhibitors (omeprazole, pantoprazole) and their mechanism of action
- M-cholinoblockers in gastroenterology (pirenzepine vs. atropine)
- Gastroprotectants (sucralfate, misoprostol) and mucosal defense
- Antacids and classification by side effect (flatulence)
- CYP2D6 isoenzyme: substrates, inhibitors, and lack of inducers
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Ranitidine" and 5,304 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.